143

(NH&d (GMP),) and Pt-GMP (Pt-(N%),d GMP), were measured with

polyclonal antibodies. The total amountof platinum (Pt) bound toDNA was also measured but with the help of atomic absorption spectroscopy (AAS). An increased net formation in GLC, compared with GLC;

CDDPis found forthetotalPtbound toDNA,Pt-GGandPt-AGadducts

after a 2 h IOU pm CDDP treatment. No significant difference is

detected in thenet formationof the I’-GMPand G-Pt-G adducts. Aslow Pt-AG adduct formation, with a maximum reached 10 h after CDDP composition, is found for both cell lines. In the 22 h period after the 2 h 100 p CDDP treatment, a significant removal in GLC, is measured for the Pt-GG, PI-AG and the Pt-GMP adducts. For GLC,-CDDPa signifi- cantremoval isdetected inthetotal PtboundtoDNA, then-AGaodthe Pt-GMP adducts. The removal of the total Pt bound to DNA in GLC,- CDDP cannot be explained by an adduct measured with the immuno- chemical method. In conclusion, no evidence is found that CDDP resistance is based upon the repair ol the Pt.GG, PtAG, G-Pt-G and Pt- GMP adducts.

This form of therapy is selective, can be applied through the broncho- scope, and is aimed at accomplishing curative elimination of central tomours of the lung. Todate, we have successfully applied PDT in four selected patients. Our first patient was treated in April, 1987. The irradiation modalities and the clinical course are described.

Apparent response of small cell lung cancer to an extract of mistle- toe and homoeopathic treatment Bradley GW, Clover A. William Ilorvey Ho&d. Ashford TN24 OLZ. Thorax 1989;44:1047-8.

A patient with small cell lung carcinoma was treated initially with extracts of mistletoe and homocopathic treatment and appeared to respond. Subsequently radiotherapy was given and the patient lived for five years seven months, which is much longer than is usual with this type of tumour.

Reviews Radiotherapy

Evaluation of lungdosecorrection methods for photon irradiations of thorax phantoms El-Khatib EE, Evans M, Pla M, Cunningham JR. Deportment of Medical Physics, Cross Cancer Inslilute, Edmonron, Aim. T6G 122. Int J Radial Oncol Biol Phys 1989; 17:87 l-8.

Radiation absorbed dose in lung is measwcd and calculated using several algorithms available on commercial treatment planning sys- tems. Phantoms resembling the human thorax are used and irradiated with small and large photon beams of “Co, 4, 6, and IO MV X ray energies. The applicabihly and usefulness of the different calculation

methods in clinical situations is discussed.

Combined treatment modalities

Optimal treatment for Tl-3NOM0 small cell lung cancer: Surgery plus adjuvant chemotherapy Macchiarini P, Mussi A, Basolo F, Bruno J, Angeletti CA. Service of Thoracic Surgery, Unwersity of Pisa, Vu Roma, 67, l-56100 Piss. Anocancer Res 1989;9:1623-6.

To improve treatment results in patients with surgically resecrable TI-3NOM0 small cell lung cancer. 16 patients were randomized to

receive either neoadjuvant (preoperative) or adjuvant (postoperative)

chemotherapy (cyclophosphamide, epirubicin, and etoposide). The

overall survival is 45% at a median follow-up of 28.5 months. Patients treated with surgery plus adjuvant chemotherapy (n = 8) showed a

significantly higher median and overall survival, proportion of 2-year survivors, and lower systemic relapse rate. These results indicate that

the optimal treatment for TI-3NOM0 small cell lung cancer is repre-

scntcd by the combmation of surgery plus adjuvant chemotherapy.

Other treatment modalities

Photodynamic treatment of cancer of lung Haussinger K, Huber RM, Krug M et al. Pneumlogische Khnik. Zentralkmnkenhaus (;auring, LVA Oherbayern, Unlerbrunnerstrasse XS, D-8035 Gaufing. Pncumologie 1990;44:687-93.

Photodynamic therapy (PDT) with porphyrin derivatives (haemato-

porphyrin and dihaematoporphyrin athcr/cster) and laser light of the

wavelength640nm, isancw procedure for the trcatmentofcarCmomas.

Bronchial carcinoid: A clinical study of 37 patients Liewald F, Dienemann H, Sunder-Plassmann L. Chirurgische Klinik

und Poliklinik. Klinikum Grosshadern der Universitar Munchen. 8000 Munchen 70. Dtsch Med Wochenschr 1989; 114: 1692-6.

To establish whether bronchoplastic procedures designed to mini- mize loss of lung tissue are justifiable for the treatment of bronchial

carcinoid turnours, data were analysed from 37 patients (I7 men, 20

women, average age 5 1 [22-701 years) who had undergone surgery for typical (n = 30) or atypical (n = 7) broncial carcinoids. Conventional tumour resections had been performed in 29 cases and bronchoplastic

operations in eight. After an average observation period of 54 months

one patient who had undergone lobectomy for a bronchial carcinoid had

died of recurrent tumour, and one other patient who had been treated by pneumonectomy for an atypical carcinoid haddeveloped distant metas- tases. All the other patients were free from tumour at that time. This indicates that patients treated by bronchoplastic proceduresdo not have any higher incidence of recurrences or any lower chance of survival than those treated by lobectomy orpneumoncctomy. A bronchoplastic

operation should therefore bc the treatment of first choice, provided tbat

the adjacent lung tissue has not been destroyed by retention pneumonia

and that lymph node dissection does not reveal any involvement.

Miscellaneous

Malignant tumors of the chest wall Briccoli A,CapannaR,Beghi Metal. PatologiaChrurgica. Universim di Modem, Via de1 Pozzo 71,441OO Modena. Chrurgia 1989;2:481-6.

20 casts of malignant tumors of the chest wall underwent surgical

therapy from 1980 to 1986. All patients were submitted to radical

surgery consisting m dissecting the pleura for a perioperative verifica-

tion with excision of wide margrns in musculoskeletal. Reconstruction

wasperformedw~thoutprosthetic replacement,according tothemetbod

of simple myoplasty. After an average follow-up of 74 months 9

patients are live: 11 cases decreased meanly at 37 months from surgery

for local recurrence. It’s therefore suggested the utility of surgical

therapy instead of other therapeutical approach.

RECPAM: A computer program for recursive partition amalga- mation for censored survival data and other situations frequently occurring in biostatistics. II. Applications to data on small cell carcinoma of the lung (SCCL) Clampi A, Thiffault I, Sagman U. Monlrenl Childrens Hospml Re- search InsUm, 4060 Ste-Carherine West. Monweal. Que. 113% 223. Comput Methods Programs Biomcd 1989;30:28.3-96.